Expert Ratings for Horizon Therapeutics
Analysts have provided the following ratings for Horizon Therapeutics (NASDAQ:HZNP) within the last quarter:
Goldman Sachs Maintains Buy on Horizon Therapeutics, Lowers Price Target to $144
Goldman Sachs analyst Madhu Kumar maintains Horizon Therapeutics (NASDAQ:HZNP) with a Buy and lowers the price target from $164 to $144.
SVB Leerink Upgrades Horizon Therapeutics to Outperform, Lowers Price Target to $80
SVB Leerink analyst David Risinger upgrades Horizon Therapeutics (NASDAQ:HZNP) from Market Perform to Outperform and lowers the price target from $95 to $80.
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers
Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.
Nasdaq Surges Over 300 Points; Moderna Earnings Beat Expectations
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Wednesday.
Why Poseida Therapeutics Almost Doubled Today, Here Are 75 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.
Dow Jumps 350 Points; Crude Oil Drops Over 2%
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 350 points on Wednesday.
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday
Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results.
Horizon Therapeutics’ Shares Tumble On Q2 Miss, Trimmed FY22 Outlook
Horizon Therapeutics plc’s (NASDAQ:HZNP) reported Q2 sales of $876.4 million, +5% Y/Y, missing the consensus of $936.10 million. The adjusted…